Prolactinoma malady

Wikipedia: A prolactinoma is a benign tumor (adenoma) of the pituitary gland that produces a hormone called...⁴⁴ more...

MalaCards: Prolactinoma, also known as pituitary adenoma, prolactin-secreting, is related to growth hormone secreting pituitary adenoma and acth-secreting pituitary adenoma. An important gene associated with Prolactinoma is CORT (cortistatin), and among its related pathways are Neuroactive ligand-receptor interaction and CREB Pathway. The compounds carbachol and threonine have been mentioned in the context of this disorder. Affiliated tissues include heart, prostate and t cells, and related mouse phenotypes are respiratory system and craniofacial.

OMIM: 600634

Aliases & Descriptions:

prolactinoma 6 7 32 43 pituitary adenoma, prolactin-secreting 6 33 prolactinoma (morphologic abnormality) 6 prolactinoma of pituitary gland 6

prolactinoma (disorder) 6 prolactinoma, familial 30 familial prolactinoma 6 pituitary adenoma 43

Diseases related to prolactinoma by text searches and GeneDecks gene sharing:

(show top 50)    (show all 668)

id	Related Disease	Score	Top Affiliating Genes
1	growth hormone secreting pituitary adenoma	35.0	CGA, CGB, MEN1, IGF1, GNAS, GH1
2	acth-secreting pituitary adenoma	34.9	LIF, LIFR, AIP, GAPDH
3	functioning pituitary adenoma	34.3	CGA, MKI67, IGF1, GNAS, GNRH1, ESR1
4	cushing's syndrome	32.2	GH1, SST, POMC
5	mccune albright syndrome	31.8	GNAS, GH1, PRL
6	carney complex	30.4	NCAM1, CHGA, MEN1, GNAS, GH1, AIP
7	headache	29.8	VIP, INS, IGF1, DRD2, SST, PRL
8	nelson syndrome	29.7	PTTG1, SST, PRL, POMC
9	lipomatosis	29.2	MEN1, HMGA2, PRKAR1A
10	primary hyperparathyroidism	29.1	PBX1, BGLAP, CHGA, MEN1, PTHLH, PRKAR1A
11	craniopharyngioma	28.9	CGA, MKI67, INS, IGF1, GH1, ERBB2
12	adrenal gland hyperfunction	28.8	BGLAP, HSD3BP4, GH1, TRH, SST, PRKAR1A
13	gigantism	28.7	INS, MEN1, IGFBP3, IGF1, GNAS, GH1
14	primary pigmented nodular adrenocortical disease	28.6	NCAM1, CHGA, GNAS, ESR1, ESR2, CTNNB1
15	prolactin producing pituitary tumor	28.5	AIP, TRH, SST, PRL, POMC
16	hypopituitarism	28.4	PBX1, CGA, INS, IGFBP3, IGF1, GNRH1
17	transsexualism	28.3	BGLAP, GNRH1, ESR1, ESR2, SHBG, KLK3
18	multiple endocrine neoplasia	28.3	VIP, PBX1, CHGB, CHGA, CDH1, INS
19	somatotrophinoma	28.3	MEN1, IGF1, GNAS, GH1, GHRHR, AIP
20	papillary thyroid carcinoma	28.0	CDH1, MEN1, MAPK1, ESR2, CTNNB1
21	cystinosis	27.7	CGA, INS, GH1, SST, PRL
22	pituitary apoplexy	27.6	INS, GNRH1, GH1, TRH, PRL, POMC
23	neuroendocrine tumor	27.5	NCAM1, VIP, CHGB, CHGA, MKI67, MEN1
24	gastritis	26.8	CHGA, CDH1, MKI67, INS, MEN1, ERBB3
25	hypogonadism	26.3	PBX1, BGLAP, CGA, INS, IGFBP3, IGF1
26	prostatic hypertrophy	26.3	FGF2, IGFBP3, IGF1, GNRH1, ESR1, SRD5A1
27	hypothyroidism	26.1	VIP, LIF, PBX1, BGLAP, CHGA, CGA
28	hyperprolactinemia	26.0	VIP, BGLAP, CGA, CGB, INS, IGFBP3
29	pituitary tumor	25.9	NCAM1, VIP, BMP2, LIF, PBX1, CHGB
30	growth hormone deficiency	25.8	VIP, PBX1, BGLAP, INS, IGFBP3, IGF1
31	renal carcinoma	25.5	MYC, CDH1, MKI67, FGF2, MEN1, MAPK1
32	polyposis	24.9	VIP, MYC, BMP2, LIFR, CHGA, JUP
33	systemic lupus erythematosus	24.8	CNTF, MYC, LIF, BGLAP, CHGA, CGA
34	insulinoma	24.7	VIP, MYC, PBX1, CHGA, FOS, INS
35	aldosteronism	24.7	VIP, BMP2, BMP4, CHGA, CGA, INS
36	lupus erythematosus	24.4	CNTF, VIP, MYC, LIF, BGLAP, CHGA
37	hyperparathyroidism	23.9	VIP, BMP2, PBX1, BGLAP, CHGA, INS
38	thyroid carcinoma	23.7	MYC, BGLAP, CGA, CDH1, FOS, MKI67
39	graves' disease	23.6	MYC, BGLAP, CGA, FOS, MKI67, MICA
40	acromegaly	23.3	VIP, PBX1, BGLAP, CHGA, CGB, INS
41	meningioma	23.3	NCAM1, MYC, BMP4, LIF, LIFR, JUP
42	pheochromocytoma	22.4	NCAM1, VIP, MYC, BMP4, LIF, CHGB
43	sinusitis	22.4	MYC, BGLAP, CGA, MKI67, INS, FGF2
44	retinoblastoma	21.4	NCAM1, VIP, MYC, BMP2, BMP4, CHGA
45	hypoxia	21.1	VIP, MYC, BMP2, BMP4, LIF, BGLAP
46	blindness	21.1	CNTF, VIP, LIF, PBX1, BGLAP, CHGA
47	pituitary adenoma	20.0	NCAM1, CNTF, VIP, MYC, BMP4, LIF
48	adenoma	17.7	NCAM1, CNTF, VIP, MYC, BMP2, BMP4
49	carcinoma	17.5	NCAM1, CNTF, VIP, MYC, BMP2, BMP4
50	neuronitis	17.3	NCAM1, CNTF, VIP, MYC, BMP2, BMP4

Clinical features from OMIM: 600634

Approved drugs:

Drug clinical trials:

MalaCards organs/tissues related to prolactinoma:

²²

MGI Mouse Phenotypes related to prolactinoma:

²⁵ (show all 27)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	respiratory system phenotype	MP:0005388	10.2	PRKAR1A, NOG, SSTR4, DRD2, LIF
2	craniofacial phenotype	MP:0005382	9.3	POU1F1, PRKAR1A, NOG, SMAD3, HMGA2, GNAS
3	liver/biliary system phenotype	MP:0005370	9.3	BMP4, LIF, PBX1, INS, MEN1, ESR2
4	endocrine/exocrine gland phenotype	MP:0005379	9.3	GNRH1, GNRHR, HMGA2, TRH, NR5A1, NRG1
5	hematopoietic system phenotype	MP:0005397	9.2	KLRK1, PRKAR1A, POU1F1, E2F1, GAPDH, SMAD4
6	immune system phenotype	MP:0005387	8.8	CNTF, GFRA1, PRKAR1A, PRL, POMC, POU1F1
7	no phenotypic analysis	MP:0003012	8.2	DRD2, PTTG1, SST, SSTR3, SSTR4, CTNNB1
8	renal/urinary system phenotype	MP:0005367	8.1	PTHLH, PTTG1, CTNNB1, SMAD4, NOG, NGFR
9	limbs/digits/tail phenotype	MP:0005371	7.9	ERBB2, DRD2, PTHLH, CTNNB1, SMAD3, NOG
10	adipose tissue phenotype	MP:0005375	7.9	MYC, HMGA2, DRD2, PTHLH, PTTG1, TGFBR2
11	hearing/vestibular/ear phenotype	MP:0005377	7.8	ESR2, HMGA2, CTNNB1, NOG, NGFR, E2F1
12	embryogenesis phenotype	MP:0005380	7.2	MYC, LIFR, PBX1, JUP, FOS, PRKAR1A
13	vision/eye phenotype	MP:0005391	6.7	NRG1, SMAD3, NOG, NGF, NGFR, TGFBR2
14	mortality/aging	MP:0010768	6.7	BMP2, NR5A1, NRG1, SMAD3, SMAD4, NOG
15	normal phenotype	MP:0002873	6.5	IGF1, IL6ST, FGF4, FGF2, INS, FOS
16	integument phenotype	MP:0010771	6.5	MYC, LIF, PBX1, JUP, FOS, IL6ST
17	tumorigenesis	MP:0002006	6.2	ERBB3, ERBB2, DRD2, CTNNB1, SMAD3, SMAD4
18	digestive/alimentary phenotype	MP:0005381	5.9	ESR2, TGFBR2, PRKAR1A, E2F1, GFRA1, NGFR
19	skeleton phenotype	MP:0005390	5.6	FGF2, FGF4, IL6ST, IGF1, GNAS, INS
20	muscle phenotype	MP:0005369	5.4	CTNNB1, NRG1, SMAD4, NOG, NGFR, GFRA1
21	behavior/neurological phenotype	MP:0005386	5.3	INS, MAPK1, GNAS, ESR2, GHRHR, GHSR
22	nervous system phenotype	MP:0003631	4.9	CNTF, IL6ST, MAPK1, GNRH1, ESR2, GHRHR
23	reproductive system phenotype	MP:0005389	4.9	PRKAR1A, PRL, POU1F1, ADCY10, ADCYAP1, E2F1
24	growth/size phenotype	MP:0005378	4.0	CHGA, CGA, JUP, CDH1, FOS, INS
25	cardiovascular system phenotype	MP:0005385	3.9	FGF2, MEN1, IL6ST, MAPK1, IGF1, GNAS
26	cellular phenotype	MP:0005384	3.1	CDH1, DRD2, PTHLH, PTTG1, SSTR1, CTNNB1
27	homeostasis/metabolism phenotype	MP:0005376	1.5	PRL, POMC, POU1F1, ADCY10, ADCYAP1, E2F1

Articles related to prolactinoma:

(show top 50)    (show all 151)

id	Title	Authors	Year	Affiliating Genes
1	Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor b iological behavior. (20063113)	Wu Z.B.... Zhuge Q.C.	2010	DRD2
2	Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. (19890024)	Lania A.G.... Colao A.	2010	GNAS, PRL
3	Correlation of alternative splicing of the D2 dopamin e receptor mRNA and estrogen receptor mRNA in the prolactinomas and gonadotrope tumors. (19252821)	Wu Z.B.... Zhang Y.Z.	2009	ESR1, ESR2
4	Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment. (19359408)	Ribeiro R.S.... Abucham J.	2009	PRL
5	Extensive personal experience. Validation of prolacti n levels in menstrual disorders and in prolactinomas. (20045798)	Batrinos M.L.	2009	PRL
6	Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. (18594989)	Vallette S.... Serri O.	2009	PRL
7	Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. (18812485)	Ono M.... Takano K.	2008	PRL
8	Nephrotic-range proteinuria in a patient with a giant prolactinoma. (18455849)	Heras M.... Duarte J.	2008	PRL
9	Cost-effectiveness analysis of two therapeutic methods for prolactinoma (18843964)	Zhen J.R.... Lin S.Q.	2008	PRL
10	Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion. (17917811)	Wu Z.B.... Zhong M.	2008	PRL
11	Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report. (17967478)	Kawabata Y.... Ono M.	2008	PRL
12	Giant prolactinomas in adolescence: an uncommon cause of blindness. (16983572)	Semple P.... Levitt N.	2007	PRL
13	IGF-1 plasma levels evaluation in prolactinoma (17057896)	Zylberberg D.... Violante A.H.	2006	IGF1, PRL, GH1
14	Mutational analysis of transforming growth factor-beta receptor type II and Smad3 tumor suppressor genes in prolactinomas. (18095113)	Ikeda H.	2006	TGFBR2, SMAD3
15	Genesis of prolactinomas: studies using estrogen-treated animals. (16809921)	Sarkar D.K.	2006	DRD2
16	Immunotherapy of prolactinoma with a T helper 1 activ ator adjuvant and autoantigens: a case report. (17337912)	Hazrati S.M.... Rashidi A.	2006	PRL
17	Treatment of pituitary gland hyperfunction: from acr omegaly to prolactinoma (17033781)	SchAoffler A.	2006	IGF1
18	Angiogenesis in prolactinomas: regulation and relationship with tumour behaviour. (16411064)	de la Torre N.G.... Wass J.A.	2005	PRL, PTTG1
19	Clinicopathology, clonality, and hormone production profile of prolactinoma (16029648)	Ma W.B.... Yoshimoto T.	2005	PRL
20	Dopamine-agonist resistant prolactinomas: diagnosis and management (16444347)	Musolino N.R.... Passos V.Q.	2005	PRL
21	Prevalence of osteopenia in men with prolactinoma. (15816365)	Naliato E.C.... Violante A.H.	2005	PRL
22	Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. (15971099)	Delgrange E.... Trouillas J.	2005	PRL
23	Immunolocalization of Pit-1 in gonadotroph nuclei is indicative of the transdifferentiation of gonadotroph to lactotroph cells in prolactinomas induced by estrogen. (15221415)	Mukdsi J.H.... Torres A.I.	2004	MYC, POU1F1
24	Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. (12552124)	Paez-Pereda M.... Arzt E.	2003	BMP4, BMP2, SMAD4
25	Laminin inhibits lactotroph proliferation and is reduced in early prolactinoma development. (12972179)	Kuchenbauer F.... PA!ez-Pereda M.	2003	DRD2, PRL
26	Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells. (12574225)	Ben-Shlomo A.... Melmed S.	2003	PRL, IL6ST, LIFR
27	The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. (12364416)	Gillam M.P.... Molitch M.E.	2002	PRL
28	Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. (12161478)	Passos V.Q.... Bronstein M.D.	2002	PRL
29	The High Mobility Group A2 gene is amplified and overexpressed in human prolactinomas. (11956103)	Finelli P.... Fusco A.	2002	HMGA2
30	Giant prolactinomas: clinical management and long-term follow up. (12186457)	Shrivastava R.K.... Post K.D.	2002	PRL
31	Fertility in prolactinomas--considerations concernin g some clinical cases (12092244)	Ionescu O.... Zbranca E.	2001	PRL
32	Effect of risperidone on prolactinoma growth in a psy chotic woman. (11020104)	Pal J.K.... Sarino W.A.	2000	PRL
33	A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature. (10908167)	Berwaerts J.... Mahler C.	2000	PRL
34	Non-random trisomies of chromosomes 5, 8 and 12 in the prolactinoma sub-type of pituitary adenomas: conventional cytogenetics and interphase FISH study. (10760821)	Finelli P.... Larizza L.	2000	PBX1
35	Prolactinoma in a child showing high MIB-1 labeling index: a case report (10875113)	Akamine S.... Yokota N.	2000	PRL
36	Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. (10546001)	Heaney A.P.... Melmed S.	1999	FGF2, PTTG1
37	Somatostatin receptor scintigraphy of a patient with a giant invasive prolactinoma. (10100234)	Meyer P.... Shapiro B.	1999	SSTR5
38	Giant prolactinoma presented as unilateral exophthalm os in a prepubertal boy: response to cabergoline. (10640900)	Krassas G.E.... Kaltsas T.	1999	PRL
39	Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. (10487698)	Jaquet P.... Enjalbert A.	1999	SSTR2, PRL, SSTR5
40	Enhanced slow wave sleep in patients with prolactinoma. (9709935)	Frieboes R.M.... Steiger A.	1998	PRL
41	Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. (9709946)	Colao A.... Lombardi G.	1998	PRL
42	Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. (8921822)	Morange I.... Jaquet P.	1996	PRL
43	Dopamine responsiveness of human prolactinoma cells as determined by the reverse hemolytic plaque assay. (7670564)	Kojima Y.... Kimura F.	1995	PRL
44	Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. (7969790)	Caccavelli L.... Enjalbert A.	1994	DRD2
45	Criteria for medical as opposed to surgical treatment of prolactinomas. (8103956)	Besser M.	1993	PRL
46	Malignant prolactinoma with extracranial metastases: a report of three cases. (8319373)	Walker J.D.... Lowe D.G.	1993	SST
47	Advances in diagnostic techniques of pituitary tumors and prolactinomas. (1591282)	Maroldo T.V.... Wilson C.B.	1992	POMC
48	Results of primary treatment with bromocriptine of prolactinomas with extrasellar extension. (2311021)	Van 'T Verlaat J.W.... Bosma N.J.	1990	PRL
49	Spontaneous prolactin transplantable tumor in the Wis tar/Furth rat (SMtTW): a new animal model of human prolactinoma. (2354457)	Trouillas J.... Chevallier P.	1990	PRL
50	Hypogonadism of male prolactinomas: relation to pulsatile secretion of LH. (2099670)	Saitoh Y.... Mogami H.	1990	PRL

Genes related to prolactinoma according to GeneCards:

(show top 50)    (show all 75)

id	Symbol	Description	Score	GeneCards Section Context
1	CORT	cortistatin	11.0	Publications
2	PRL	prolactin	11.0	Publications
3	PTTG1	pituitary tumor-transforming 1	11.0	Publications
4	FGF4	fibroblast growth factor 4	11.0	Publications
5	SSTR1	somatostatin receptor 1	11.0	Publications
6	SSTR4	somatostatin receptor 4	11.0
7	SSTR5	somatostatin receptor 5	11.0	Publications
8	AIP	aryl hydrocarbon receptor interacting protein	11.0
9	MEN1	multiple endocrine neoplasia I	11.0	Publications
10	POU1F1	POU class 1 homeobox 1	11.0	Publications
11	CHGB	chromogranin B (secretogranin 1)	11.0
12	SSTR3	somatostatin receptor 3	11.0
13	TRHR	thyrotropin-releasing hormone receptor	11.0
14	NGFR	nerve growth factor receptor	11.0	Publications
15	LIFR	leukemia inhibitory factor receptor alpha	11.0	Publications
16	PRKAR1A	protein kinase, cAMP-dependent, regulatory, type I, alpha	11.0	Publications
17	GHRHR	growth hormone releasing hormone receptor	11.0
18	SSTR2	somatostatin receptor 2	11.0	Publications
19	GNRHR	gonadotropin-releasing hormone receptor	11.0	Publications
20	DRD2	dopamine receptor D2	11.0	Publications
21	IL6ST	interleukin 6 signal transducer (gp130, oncostatin M receptor)	11.0	Publications
22	HMGA2	high mobility group AT-hook 2	11.0	Publications
23	JUP	junction plakoglobin	11.0	Publications
24	NR5A1	nuclear receptor subfamily 5, group A, member 1	11.0
25	GHSR	growth hormone secretagogue receptor	11.0
26	ADCYAP1	adenylate cyclase activating polypeptide 1 (pituitary)	11.0
27	CNTF	ciliary neurotrophic factor	11.0
28	TRH	thyrotropin-releasing hormone	11.0
29	BMP4	bone morphogenetic protein 4	11.0	Publications
30	CGB	chorionic gonadotropin, beta polypeptide	11.0
31	NGF	nerve growth factor (beta polypeptide)	11.0	Publications
32	SST	somatostatin	11.0	Publications
33	CHGA	chromogranin A (parathyroid secretory protein 1)	11.0	Publications
34	GFRA1	GDNF family receptor alpha 1	11.0
35	LIF	leukemia inhibitory factor	11.0	Publications
36	GNRH1	gonadotropin-releasing hormone 1 (luteinizing-releasing hormone)	11.0	Publications
37	GAL	galanin prepropeptide	11.0
38	E2F1	E2F transcription factor 1	11.0
39	PTHLH	parathyroid hormone-like hormone	11.0
40	POMC	proopiomelanocortin	11.0	Publications
41	PBX1	pre-B-cell leukemia homeobox 1	11.0	Publications
42	GH1	growth hormone 1	11.0	Publications
43	GNAS	GNAS complex locus	11.0	Publications
44	GAPDH	glyceraldehyde-3-phosphate dehydrogenase	11.0
45	ESR2	estrogen receptor 2 (ER beta)	11.0	Publications
46	CGA	glycoprotein hormones, alpha polypeptide	11.0	Publications
47	ADCY10	adenylate cyclase 10 (soluble)	11.0
48	IGF1	insulin-like growth factor 1 (somatomedin C)	11.0	Publications
49	NCAM1	neural cell adhesion molecule 1	11.0
50	ESR1	estrogen receptor 1	11.0	Publications

Pathways related to prolactinoma according to GeneDecks:

(show top 50)    (show all 124)

id	Pathway	Score	Top Affiliating Genes
1	Neuroactive ligand-receptor interaction20	10.1	GHSR, SSTR4, SSTR3, SSTR1, SSTR5, PRL
2	CREB Pathway36	9.9	PRKAR1A, BMP2, FGF4, BMP4, IGF1, GNRH1
3	Development Role of Activin A in cell differentiation and proliferation10	9.6	SMAD4, SMAD3, GNRHR, GNAS, CGA, PBX1
4	Development_Role of Activin A in cell differentiation and proliferation41	9.6	MYC, PBX1, PRKAR1A, CGA, GNAS, GNRHR
5	Colorectal cancer20	9.5	TGFBR2, SMAD3, FOS
6	Development_Ligand-independent activation of ESR1 and ESR241	9.3	PRKAR1A, ERBB2, ERBB3, ESR2, ESR1, IGF1
7	JNK Pathway36	9.3	BMP2, NRG1, FGF2, FGF4, LIFR, NGFR
8	Akt Signaling36	9.2	NGFR, BMP2, BMP4, LIF, ERBB3, FGF4
9	NF-KappaB (p50-p65) Pathway36	8.9	PRKAR1A, BMP4, BMP2, NGFR, NRG1, GH1
10	Apoptotic Pathways in Synovial Fibroblasts36	8.9	NGFR, NRG1, GH1, GNRH1, IGF1, FGF4
11	Transcription_Androgen Receptor nuclear signaling41	8.9	MAPK1, IGF1, SRD5A1, CTNNB1, SMAD3, KLK3
12	Transcription Androgen Receptor nuclear signaling10	8.9	MAPK1, IL6ST, IGF1, SRD5A1, CTNNB1, SMAD3
13	ERK5 Signaling36	8.9	FOS, MYC, BMP2, FGF4, IL6ST, GNRH1
14	TGF-beta signaling pathway20	8.8	SMAD4, MAPK1, BMP4, SMAD3, NOG, MYC
15	Telomerase Components in Cell Signaling36	8.8	NGFR, GH1, NRG1, GNRH1, IGF1, FGF4
16	Nuclear Receptor Activation by Vitamin-A36	8.7	FGF4, BMP2, BMP4, FGF2, PRKAR1A, NGFR
17	PPAR Pathway36	8.7	BMP2, NRG1, NGFR, FGF2, FGF4, GH1
18	p53 Mediated Apoptosis36	8.4	GNRH1, NGFR, FGF2, BMP2, BMP4, FGF4
19	Breast Cancer Regulation by Stathmin136	8.3	BMP2, E2F1, LIFR, FGF2, FGF4, ERBB3
20	Development Ligand-independent activation of ESR1 and ESR210	8.3	ERBB3, ESR2, ESR1, GNAS, MAPK1, NRG1
21	TGF-beta Signaling Pathways37	8.3	FOS, MAPK1, ESR1, ESR2, SMAD3, SMAD4
22	eIF2 Pathway36	8.3	BMP4, FGF2, FGF4, MAPK1, IGF1, INS
23	Renin-Angiotensin Pathway36	8.1	GH1, NRG1, NGFR, PRKAR1A, GNRH1, IGF1
24	Paxillin Interactions36	8.0	BMP2, ERBB3, NRG1, ERBB2, BMP4, LIFR
25	p70S6K Signaling36	8.0	GNRH1, FGF4, NGFR, BMP2, BMP4, INS
26	mTOR Pathway36	7.9	NRG1, GNRH1, BMP2, IGF1, GH1, BMP4
27	Antioxidant Action of Vitamin-C36	7.9	FGF2, LIFR, LIF, BMP4, BMP2, NRG1
28	eNOS Signaling36	7.8	PRKAR1A, NRG1, ERBB2, ERBB3, GH1, ESR2
29	P2Y Receptor Signaling36	7.8	ERBB3, ERBB2, LIFR, PRKAR1A, MAPK1, FGF4
30	p38 Signaling36	7.7	FGF4, FGF2, GNRH1, IGF1, BMP2, BMP4
31	ERK Signaling36	7.7	BMP2, BMP4, LIFR, FGF4, MAPK1, GNRH1
32	Epithelial Adherens Junctions36	7.6	BMP4, BMP2, TGFBR2, NRG1, CTNNB1, ERBB2
33	TGF-Beta Pathway36	7.6	GNRH1, NGFR, NRG1, BMP2, GH1, IGF1
34	14-3-3 Induced Intracellular Signaling36	7.6	IGF1, BMP4, LIFR, FGF2, FGF4, BMP2
35	Tec Kinases Signaling36	7.5	FOS, FGF2, ERBB3, NGFR, FGF4, NRG1
36	Rap1 Pathway36	7.5	BMP2, BMP4, LIFR, FGF2, FGF4, MAPK1
37	Activation of PKA through GPCR36	7.5	GNRH1, GH1, ERBB3, NRG1, PRKAR1A, IGF1
38	Ras Pathway36	7.4	BMP4, LIFR, FOS, MAPK1, FGF2, FGF4
39	Nanog in Mammalian ESC Pluripotency36	7.4	IGF1, FGF4, MAPK1, GNRH1, GH1, ERBB3
40	Pancreatic Adenocarcinoma36	7.3	IGF1, GNRH1, GH1, ERBB3, ERBB2, NRG1
41	NFAT in Immune Response36	7.1	FGF2, FOS, LIFR, BMP4, NRG1, FGF4
42	GPCR Pathway36	7.1	ERBB2, BMP2, PRKAR1A, NRG1, FGF2, FGF4
43	GSK3 Signaling36	7.1	NRG1, ERBB3, CTNNB1, GNRH1, IGF1, MAPK1
44	Molecular Mechanisms of Cancer36	6.9	FOS, CDH1, LIF, BMP4, BMP2, MYC
45	Pathways in cancer20	6.9	TGFBR2, E2F1, SMAD4, CTNNB1, ERBB2, MAPK1
46	Estrogen Pathway36	6.9	NRG1, ESR2, GH1, ERBB3, ERBB2, PRKAR1A
47	JAK-STAT Pathway36	6.8	ERBB2, MYC, BMP2, BMP4, MAPK1, GNRH1
48	MAPK Signaling36	6.7	GNRH1, NGFR, GH1, ERBB3, ERBB2, NRG1
49	Rho Family GTPases36	6.7	GNRH1, NRG1, ERBB2, ERBB3, GH1, IGF1
50	ILK Signaling36	6.3	LIFR, CDH1, FOS, BMP2, CTNNB1, BMP4

Compounds related to prolactinoma according to GeneDecks:

(show top 50)    (show all 325)

id	Compound	Score	Top Affiliating Genes
1	carbachol32 9 9	12.6	CGA, SST
2	threonine32	9.8	BMP2, GNAS, NR5A1, NRG1, GAL
3	bromocriptine32 9 9	11.7	VIP, GNRH1, GNRHR, GH1, TRH, SST
4	rapamycin32 42	10.5	BMP2, BMP4, INS, ERBB3, SST, ADCYAP1
5	progestin32	9.5	LIF, CGA, CDH1, GNRH1, HSD3BP4, ESR2
6	glucose32	9.3	CNTF, CGB, MKI67, GHRHR, GHSR, ERBB3
7	hexarelin32	9.2	PBX1, IGFBP3, IGF1, GH1, GHRHR, GHSR
8	leuprolide acetate32	9.2	CGA, IGF1, GNRH1, GNRHR, ESR1, ESR2
9	ghrp32	9.1	PBX1, IGFBP3, IGF1, GH1, GHRHR, GHSR
10	naloxone32 34 9 9	11.9	VIP, CGA, FOS, GNRH1, ESR1, GH1
11	estradiol32 9 18 9	11.5	LIF, PBX1, CGA, CGB, MKI67, GNRHR
12	androstenedione32 18	9.5	PBX1, CGA, CGB, INS, IGFBP3, IGF1
13	dehydroepiandrosterone sulfate32	8.3	CGA, INS, IGFBP3, IGF1, GNRH1, HSD3BP4
14	dhea32	8.2	INS, IGFBP3, IGF1, HSD3BP4, ESR2, GH1
15	pge232	8.0	CNTF, VIP, BMP2, BMP4, LIF, CGA
16	agar32	7.8	JUP, CDH1, FGF2, FGF4, ERBB3, ERBB2
17	raloxifene32 9 9	9.8	BMP2, BGLAP, CDH1, IGFBP3, IGF1, GNRH1
18	norepinephrine32 9 18 9	10.7	CNTF, VIP, LIF, CHGB, CHGA, CGA
19	tgf beta132	7.7	BMP2, BMP4, LIF, CDH1, MKI67, FGF2
20	retinoid32	7.7	MYC, BMP2, BMP4, CDH1, FOS, FGF4
21	matrigel32	7.6	NCAM1, BMP2, LIF, CHGA, CGB, CDH1
22	ly29400232	7.5	CDH1, FOS, FGF2, MAPK1, ERBB2, NRG1
23	heparin32 9 18 9	10.5	NCAM1, BMP4, LIF, BGLAP, CGA, CDH1
24	calcitriol32 42 9 18 9	11.4	MYC, BMP2, LIF, BGLAP, CDH1, FOS
25	octreotide32 42 9 9	10.4	VIP, CHGA, MKI67, INS, IGFBP3, IGF1
26	acetylcholine32 9 18 9	10.2	NCAM1, CNTF, VIP, LIF, CHGA, CGA
27	thyroxine32 18	8.0	VIP, BGLAP, CGA, CGB, FOS, INS
28	dopamine32 9 18 9	10.0	NCAM1, CNTF, VIP, BMP2, LIF, CHGB
29	oligonucleotide32	6.9	MYC, BMP2, BMP4, LIF, LIFR, CHGB
30	phosphatidylinositol32	6.7	NCAM1, CNTF, MYC, BMP4, LIF, FOS
31	gnrh32	6.6	NCAM1, PBX1, CGB, MKI67, INS, IGFBP3
32	dihydrotestosterone32 9 18 9	9.4	VIP, BMP2, BGLAP, CGA, CDH1, FGF2
33	arginine32	6.3	CNTF, VIP, BMP2, LIF, PBX1, BGLAP
34	vitamin d32	6.1	BMP2, BGLAP, CHGA, CGA, CDH1, MEN1
35	genistein32 9 18 9	9.0	CNTF, MYC, BMP2, LIF, CDH1, FOS
36	cisplatin32 34 9 9	9.0	MYC, LIF, BGLAP, CHGA, CGA, CGB
37	paclitaxel32 34 9 9	9.0	MYC, LIF, LIFR, CHGA, JUP, CDH1
38	calcium32 9 18 9	8.7	CNTF, VIP, BMP2, BMP4, LIF, BGLAP
39	steroid32	5.6	BMP2, LIF, LIFR, PBX1, CHGA, CGA
40	paraffin32	5.4	NCAM1, MYC, LIF, BGLAP, CHGA, CGA
41	thymidine32 18	6.2	CNTF, VIP, MYC, BMP2, BMP4, LIF
42	glutamate32	5.2	NCAM1, VIP, CDH1, FOS, INS, MAPK1
43	tamoxifen32 34 9 9	8.1	MYC, BGLAP, CHGA, CGA, CDH1, FOS
44	testosterone32 9 18 9	7.2	NCAM1, CNTF, VIP, BMP2, LIF, PBX1
45	estrogen32	3.8	VIP, BMP2, BMP4, LIFR, BGLAP, CHGB
46	cycloheximide32	3.5	CNTF, MYC, BMP2, BMP4, LIF, CHGA
47	dexamethasone32 42 34 9 9	6.8	NCAM1, VIP, MYC, BMP2, BMP4, LIF
48	tyrosine32	2.7	NCAM1, CNTF, VIP, MYC, BMP2, BMP4
49	vegf32	2.0	NCAM1, CNTF, VIP, MYC, BMP2, BMP4
50	serine32	1.7	NCAM1, CNTF, VIP, MYC, BMP2, BMP4

Cellular components related to prolactinoma according to GeneDecks:

(show all 12)

id	Name	GO ID	Score	Top Affiliating Genes
1	SMAD protein complex	GO:071141	10.1	HMGA2, SMAD3, SMAD4
2	membrane-bounded vesicle	GO:031988	9.9	BGLAP, BMP4, BMP2
3	catenin complex	GO:016342	9.9	JUP, CDH1, CTNNB1
4	lateral plasma membrane	GO:016328	9.8	CTNNB1, DRD2, ERBB3, CDH1, JUP
5	protein-DNA complex	GO:032993	9.8	CTNNB1, HMGA2, JUP
6	secretory granule	GO:030141	9.7	GAL, POMC, TRH, GHRHR, INS, CHGA
7	cell surface	GO:009986	9.3	NGFR, TRHR, GHSR, GHRHR, MICA, CDH1
8	receptor complex	GO:043235	9.2	TGFBR2, SMAD3, ERBB2, ERBB3
9	integral to plasma membrane	GO:005887	9.0	NRG1, SSTR5, SSTR4, SSTR3, SSTR2, SSTR1
10	plasma membrane	GO:005886	7.2	DRD2, SSTR1, SSTR2, SSTR3, SSTR4, SSTR5
11	extracellular space	GO:005615	6.7	GH1, ERBB3, PTHLH, SST, NRG1, NOG
12	extracellular region	GO:005576	5.5	GAL, ESR2, GH1, TRH, PTHLH, SST

Biological processes related to prolactinoma according to GeneDecks:

(show top 50)    (show all 51)

id	Name	GO ID	Score	Top Affiliating Genes
1	somatostatin signaling pathway	GO:038170	10.7	SSTR5, SSTR4, SSTR3, SSTR2, SSTR1
2	G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	GO:007187	10.7	SSTR1, SSTR2, SSTR3, SSTR4, SSTR5
3	ciliary neurotrophic factor-mediated signaling pathway	GO:070120	10.7	IL6ST, LIFR, CNTF
4	leukemia inhibitory factor signaling pathway	GO:048861	10.7	LIF, LIFR, IL6ST
5	growth hormone secretion	GO:030252	10.6	GHRHR, GHSR, GAL
6	positive regulation of multicellular organism growth	GO:040018	10.6	DRD2, GHSR, GHRHR, GH1
7	positive regulation of tyrosine phosphorylation of Stat3 protein	GO:042517	10.5	GH1, IL6ST, LIF, CNTF
8	cellular response to estradiol stimulus	GO:071392	10.5	SRD5A1, SSTR3, SSTR2
9	negative regulation of cell cycle	GO:045786	10.4	NGFR, NGF, MEN1, BMP4, BMP2
10	positive regulation of astrocyte differentiation	GO:048711	10.4	BMP2, LIF, IL6ST
11	lung lobe morphogenesis	GO:060463	10.4	TGFBR2, IGF1, LIF
12	lung alveolus development	GO:048286	10.4	PTHLH, IGF1, LIF, BMP4
13	female pregnancy	GO:007565	10.3	ADCYAP1, PRL, PTHLH, GNRH1, GNAS
14	cellular response to indole-3-methanol	GO:071681	10.3	CTNNB1, CDH1, JUP
15	positive regulation of insulin-like growth factor receptor signaling pathway	GO:043568	10.2	GHSR, GHRHR, GH1, IGF1, IGFBP3
16	osteoblast development	GO:002076	10.2	SMAD3, PTHLH, MEN1, BGLAP
17	pituitary gland development	GO:021983	10.1	BMP4, CDH1, SRD5A1, NOG
18	activation of MAPKK activity	GO:000186	10.1	BMP4
19	epithelial to mesenchymal transition	GO:001837	10.1	NOG, CTNNB1, HMGA2, BMP2
20	positive regulation of fibroblast proliferation	GO:048146	10.1	E2F1, NGFR, IGF1, MYC
21	positive regulation of osteoblast differentiation	GO:045669	10.0	IGF1, IL6ST, MEN1, FGF2, BMP4, BMP2
22	response to mechanical stimulus	GO:009612	9.9	BMP2, BMP4, BGLAP, NGF
23	osteoblast differentiation	GO:001649	9.9	BMP4, BGLAP, NOG
24	SMAD protein signal transduction	GO:060395	9.9	SMAD4, FOS, BMP4, BMP2
25	positive regulation of ERK1 and ERK2 cascade	GO:070374	9.9	BMP2, BMP4, FGF2, FGF4, DRD2
26	positive regulation of phosphatidylinositol 3-kinase cascade	GO:014068	9.9	ERBB3, GH1, IGF1, INS, CNTF
27	cellular response to growth factor stimulus	GO:071363	9.8	CTNNB1, SRD5A1, BMP4, BMP2
28	G-protein coupled receptor signaling pathway	GO:007186	9.7	SSTR5, SSTR4, SST, TRHR, GHSR, GNRHR
29	branching involved in ureteric bud morphogenesis	GO:001658	9.7	SMAD4, FGF2, BMP4, BMP2, MYC
30	positive regulation of MAPK cascade	GO:043410	9.7	IGF1, IGFBP3, INS, LIF, CNTF
31	transcription initiation from RNA polymerase II promoter	GO:006367	9.6	SMAD4, SMAD3, NR5A1, ESR2, ESR1, MEN1
32	positive regulation of apoptotic process	GO:043065	9.6	GAL, ADCY10, CTNNB1, HMGA2, ESR2, IGFBP3
33	cell surface receptor signaling pathway	GO:007166	9.5	PRL, GFRA1, SSTR1, SST, ERBB2, LIFR
34	positive regulation of epithelial cell proliferation	GO:050679	9.4	NOG, ERBB2, IGF1, BMP4, MYC
35	transforming growth factor beta receptor signaling pathway	GO:007179	9.3	TGFBR2, SMAD4, SMAD3, MEN1, FOS, MYC
36	negative regulation of transcription from RNA polymerase II promoter	GO:000122	9.3	E2F1, NOG, SMAD4, SMAD3, HMGA2, ESR2
37	negative regulation of protein catabolic process	GO:042177	9.3	INS, NRG1, SMAD3, SMAD4
38	glial cell differentiation	GO:010001	9.2	NRG1, IGF1, FGF2
39	in utero embryonic development	GO:001701	9.2	TGFBR2, NOG, SMAD4, SMAD3, CTNNB1, BMP2
40	cell-cell signaling	GO:007267	9.1	ADCYAP1, BMP2, CGA, CGB, INS, FGF4
41	transmembrane receptor protein tyrosine kinase signaling pathway	GO:007169	9.0	ADCYAP1, NGF, NRG1, ERBB2, ERBB3
42	response to drug	GO:042493	8.8	GAL, TGFBR2, NGF, CTNNB1, SRD5A1, SST
43	MAPK cascade	GO:000165	8.8	NRG1, MAPK1, MEN1, INS, MYC
44	negative regulation of transcription, DNA-dependent	GO:045892	8.7	E2F1, SMAD4, NRG1, CTNNB1, HMGA2, MEN1
45	positive regulation of cell proliferation	GO:008284	8.5	IL6ST, IGF1, GHRHR, PTHLH, NGF, TGFBR2
46	negative regulation of cell proliferation	GO:008285	8.4	POU1F1, SMAD4, CTNNB1, SSTR5, BMP2, BMP4
47	positive regulation of transcription, DNA-dependent	GO:045893	8.1	CTNNB1, SMAD3, SMAD4, POU1F1, E2F1, HMGA2
48	positive regulation of transcription from RNA polymerase II promoter	GO:045944	8.0	DRD2, CTNNB1, NR5A1, SMAD3, SMAD4, NOG
49	wound healing	GO:042060	8.0	NOG, SMAD3, NRG1, ERBB2, ERBB3, FGF2
50	signal transduction	GO:007165	7.9	ESR2, AIP, ERBB3, ERBB2, TRH, PRKAR1A

Molecular functions related to prolactinoma according to GeneDecks:

(show all 15)

id	Name	GO ID	Score	Top Affiliating Genes
1	somatostatin receptor activity	GO:004994	10.6	SSTR5, SSTR4, SSTR3, SSTR2, SSTR1
2	growth hormone-releasing hormone receptor activity	GO:016520	10.5	GHSR, GHRHR, GNRHR
3	ciliary neurotrophic factor receptor binding	GO:005127	10.4	IL6ST, LIFR, CNTF
4	neuropeptide hormone activity	GO:005184	10.2	GAL, ADCYAP1, CORT, TRH, VIP
5	SMAD binding	GO:046332	9.8	TGFBR2, CTNNB1, HMGA2, BMP2
6	growth factor binding	GO:019838	9.5	ERBB2, ERBB3, GHRHR, IL6ST, LIFR
7	R-SMAD binding	GO:070412	9.5	SMAD4, SMAD3, CTNNB1, MEN1, FOS
8	transcription factor binding	GO:008134	9.5	E2F1, SMAD3, CTNNB1, AIP, HMGA2, PBX1
9	double-stranded DNA binding	GO:003690	9.5	SMAD3, NR5A1, CTNNB1, MEN1, MYC
10	hormone activity	GO:005179	9.1	VIP, POMC, PRL, SST, PTHLH, GH1
11	protein phosphatase binding	GO:019903	9.1	JUP, CDH1, ERBB2, CTNNB1
12	protein homodimerization activity	GO:042803	9.0	SHBG, NOG, SMAD4, SMAD3, TRHR, ERBB3
13	growth factor activity	GO:008083	8.9	NGF, NRG1, GH1, IGF1, FGF4, FGF2
14	cytokine activity	GO:005125	8.7	NRG1, FGF2, LIF, BMP4, BMP2, CNTF
15	protein binding	GO:005515	2.7	SSTR3, SSTR2, PTTG1, DRD2, ERBB2, ERBB3